As At: 3 May 2026
Introduction
This practice note explains the fundamental differences between exclusive and non-exclusive licensing in research and development. Exclusive licensing grants the licensee sole rights to use, develop, and commercialize the technology within a defined scope, preventing others from doing so. Non-exclusive licensing allows multiple licensees to access and use the technology simultaneously, promoting broader dissemination and collaboration. Understanding these distinctions is crucial for strategic decision-making, balancing commercialization incentives with public access and impact.
1. Strategic Context
Licensing decisions in R&D are no longer binary. Institutions and companies increasingly adopt hybrid models that combine exclusivity in defined fields with non-exclusive rights elsewhere. This reflects:
- The rise of open innovation ecosystems
- Pressure to align with ESG and SDG commitments
- Regulatory emphasis on public benefit and equitable access
2. Comparative Overview
| Licensing Model | Advantages | Risks | Best Use Cases |
| Exclusive | Strong incentive for commercialization; higher royalty potential; clear market positioning | Risk of “shelving” technology; reduced access; regulatory scrutiny | High-investment technologies (pharma, biotech) |
| Non-Exclusive | Broad dissemination; supports public interest; fosters collaboration | Lower revenue per licensee; weaker commercialization incentives | Platform technologies, research tools, software |
| Hybrid (Field-of-Use / Tiered) | Balances exclusivity with access; flexible revenue models; supports ESG goals | Complex drafting; monitoring obligations | Climate tech, agri-biotech, dual-use innovations |
3. Regulatory and Policy Considerations
- South Africa (IPR Act, 2008 & NIPMO guidance): Institutions must balance exclusivity with obligations to ensure public benefit, particularly in health and agriculture.
- Global frameworks:
- TRIPS flexibilities allow governments to intervene in cases of public health or essential technologies.
- WIPO discussions emphasize equitable access to innovation in climate and pharmaceutical sectors.
4. ESG and Public Interest Dimensions
- Sustainability-linked licensing: Clauses tying royalties or milestones to environmental or social impact metrics.
- Equitable access obligations: Non-exclusive licensing used to meet commitments under SDGs (e.g., food security, public health).
5. Practical Drafting Considerations
- Field-of-use restrictions: Define exclusivity narrowly to avoid blocking broader applications.
- Performance obligations: Require exclusive licensees to meet commercialization milestones; include “use it or lose it” provisions.
- Termination triggers: Retain rights to revoke exclusivity if public benefit is not achieved.
- Revenue-sharing models: Consider tiered royalties or milestone payments to balance exclusivity with broader impact.
6. Checklist for Technology Transfer Offices (TTOs)
Before granting exclusivity, assess:
- Commercial potential and investment requirements
- Social and environmental impact
- Compliance with local and international frameworks
- Performance obligations and monitoring mechanisms
- Options for hybrid or tiered licensing structures
7. Key Takeaways
- Exclusivity is not absolute: Hybrid models are increasingly the norm.
- Public benefit is central: ESG and SDG-linked obligations shape licensing decisions.
- Drafting discipline matters: Field-of-use, performance obligations, and termination triggers are essential safeguards.
Disclaimer: This practice note provides general guidance on licensing strategies and does not constitute legal advice. Institutions should consult with qualified legal and regulatory professionals to address specific circumstances and ensure compliance with applicable laws and policies.